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Twenty-four middle-aged healthy men were given a low-fat high-carbohydrate (5.5 g fat; L), or a
moderately-fatty, (25.7 g fat; M) breakfast of similar energy contents for 28 d. Other meals were
under less control. An oral glucose tolerance test (OGTT) was given at 09.00 hours on day 1
before treatment allocation and at 13.30 hours on day 29. There were no significant treatment
differences in fasting serum values, either on day 1 or at the termination of treatments on day 29.
The following was observed on day 29: (1) the M breakfast led to higher OGTT C-peptide
responses and higher areas under the curves (AUC) of OGTT serum glucose and insulin
responses compared with the OGTT responses to the L breakfast (P < 0.05); (2) treatment M
failed to prevent OGTT glycosuria, eliminated with treatment L; (3) serum non-esterified fatty
acid (NEFA) AUC was 59 % lower with treatment L than with treatment M, between 09.00 and
13.20 hours (P < 0.0001), and lower with treatment L than with treatment M during the OGTT
(P = 0.005); (4) serum triacylglycerol (TAG) concentrations were similar for both treatments,
especially during the morning, but their origins were different during the afternoon OGTT when
the Svedberg flotation unit 20–400 lipid fraction was higher with treatment L than with treatment
M (P = 0.016); plasma apolipoprotein B-48 level with treatment M was not significantly greater
than that with treatment L (P = 0.086); (5) plasma tissue plasminogen-activator activity increased
after breakfast with treatment L (P = 0.0008), but not with treatment M (P = 0.80). Waist:hip
circumference was positively correlated with serum insulin and glucose AUC and with fasting
LDL-cholesterol. Waist:hip circumference and serum TAG and insulin AUC were correlated
with factors of thrombus formation; and the OGTT NEFA and glucose AUC were correlated. A
small difference in fat intake at breakfast has a large influence on circulating diurnal NEFA
concentration, which it is concluded influences adversely glucose tolerance up to 6 h later.
Dietary fat: Carbohydrate tolerance: Insulin
High concentrations of circulating non-esterified fatty acids
(NEFA) may contribute to the insulin-resistant state (Frayn
et al. 1997; Prins, 1997). The concentration of peripheral
venous NEFA following a meal reflects leak-back from the
action of lipoprotein lipase (EC 3.1.1.34; LPL) and the
action of intracellular hormone-sensitive lipase (EC 3.1.1.3;
HSL) of adipose tissue (Frayn, 1993). A rise in postprandial
blood insulin concentration suppresses the activity of intra-
cellular HSL; but intra-abdominal fat is metabolically very
active and has a lower sensitivity than subcutaneous fat to
the inhibitory effects of insulin (Bjorntorp, 1990). This is
likely to be a cause of the positive association of intra-
abdominal fat and of waist:hip circumference (W : H)
measurements, with risk factors of cardiovascular disease
(Williams et al. 1997) and with risk of stroke (Walker et al.
1996). We have previously found (Frape et al. 1997b) that
subjects are generally more resistant to insulin at breakfast
than at lunch, leading to high circulating levels of insulin
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after breakfast; whether this is reflected in the circulating
level of NEFA is unclear.
Using healthy middle-aged men, who ranged in W : H
from 0.80 to 1.05, the purpose of the present study was to
determine to what extent small and widely observed iso-
energetic differences in breakfast fat and carbohydrate
intakes affect glucose tolerance measured several hours
later in an oral glucose tolerance test (OGTT). The purpose
was also to determine whether these responses were corre-
lated with risk factors of atherosclerosis and thrombosis.
The assertion that intolerance would be increased by the
fatty breakfast stemmed from the observation previously
reported (Frape et al. 1997b) that the glucose response to a
fatty lunch was increased by a fatty breakfast. Moreover, the
plasma NEFA concentration after this lunch was higher than
that for subjects given a carbohydrate breakfast of similar
energy content before the fatty lunch (Frape et al. 1997a).
Materials and methods
Twenty-four healthy, non-smoking Caucasian males, 35–65
years of age, were selected subsequent to medical examina-
tion and clinical analysis of blood samples. There were
twelve pairs matched according to the characteristic W : H ·
fasting LDL-cholesterol.
The two dietary treatments were allocated at random
within each pair. The treatments were a high-carbohydrate
low-fat cereal breakfast (L; composed of 86 g corn flakes þ
300 ml semi-skimmed milk þ 250 ml orange juice), or a
moderately-fatty breakfast (M; a pasty weighing 86 g,
composed of a lean meat–vegetable mixture in a pastry
covering, in which the fat was predominately butter;
Table 1). The two treatments provided similar amounts of
metabolizable energy (ME), and were each taken with one
cup of tea or coffee on days 2–28, at home before 09.00
hours, but neither tea nor coffee was given on day 29. All
subjects were provided with an evening meal of low-fat
cereal that was eaten exclusively at 19.00 hours on days 0
and 28 and they were then fasted until 09.00 hours on days 1
and 29. By analysis, treatment L provided 6.5 % more ME
than M on days 2–28. On day 29 the difference was lessened
to 2.7 % by proportionately increasing treatment M. On days
2–28 some freedom was given in the composition of the two
other daily meals taken at mid-day and in the evening. High-
fat foods were avoided, fish was excluded, and all meals
were taken at home, but recorded in a diary and assessed
using data provided by Paul & Southgate (1978) and Hol-
land et al. (1988, 1989), with dietary fibre estimated from
their tables by the method of Southgate (Wenlock et al.
1985). These two meals provided an estimated mean of 8.8
MJ ME per subject daily and contained for treatments L and
M respectively an estimated mean (g) of: fat 80 and 77, SED
4.3; protein 94 and 101, SED 10.5; carbohydrate 258 and
256, SED 36.7; dietary fibre 22 and 28, SED 3.8. None of
these differences was significant (P < 0.05). In the two
meals fat provided approximately 33 % of the energy,
protein 19 % and carbohydrate 47 %. Subjects were prohib-
ited from taking any drug containing salicylic acid, or
sodium salicylate, and none smoked or received prescription
drug treatment during the course of the study.
On day 1 fasting blood characteristics were measured and
all subjects were given an OGTT at 09.00 hours. In our
laboratory 75 g glucose leads to unacceptable glucosuria in
middle-aged subjects, causing a systematic error; thus, 66 g
glucose monohydrate (60 g glucose) were given in approxi-
mately 400 ml water. On day 29 each subject received their
previously allocated L or M breakfast at 09.00 hours,
followed at 13.30 hours by an OGTT. Water was available
for drinking on both days 1 and 29. Urination did not occur
between 0 and 130 min following each glucose dose, and
then a urine sample was provided at 130 min following each
dose. All test meals and metabolic measurements were
carried out at Papworth Hospital, Cambridge, and were
synchronized within each pair on days 1 and 29.
Response measurements
Body weight, height and the circumference at the waist and
hips were recorded ‘blind’ by the same nurse, when fasting,
at the same time of day during medical examination on days
1 and 29. W : H values varied from 0.80 to 1.05 and the
measurements were made at the levels of the umbilicus and
the greater trochanter of the femur. An indwelling ante-
cubital vein cannula was fitted at 08.00 hours on days 1 and
29. Blood samples (12 ml) were taken on each day pre-
OGTT and at 30, 60, 90 and 120 min following the glucose
dose on days 1 and 29. On day 29, blood (12 ml) was also
taken when fasting and at 60, 120, 180 and 260 min after
breakfast. The 260 min sample served also as the pre-OGTT
sample on day 29. All subjects were seated between blood
sampling times and during phlebotomy. The cannulas were
kept patent by injection of 2 ml physiological saline (9 g
NaCl/l) after sampling. During phlebotomy the first sample
of 2 ml was discarded and subsequent samples were held in
Sarstedt Monovettet tubes (Sarstedt, Leicester, UK) of the
following types: serum gel for measurement of fasting
cholesterol, NEFA, glycerol, glucose, insulin and C-pep-
tide; citrate for haematology and platelet aggregation;
Stabilytet for tissue plasminogen-activator (t-PA) activity
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Table 1. Mean composition (g) of a moderately-fatty pasty and a high-
carbohydrate low-fat corn flakes meal by chemical analysis*
Cereal† meal Pasty meal
Moisture ND 65.1
Protein (N · 6.25) 18.4 18.8
Fat (Bligh & Dyer, 1959) 5.5 25.7
Ash ND 3.8
Total carbohydrate 113.0 55.9
Dietary fibre 0.9 3.5
Available carbohydrate 113.0 52.3
Total sugars, as glucose 46.1 4.2
Saturated fatty acids 3.1 14.4
Monounsaturated fatty acids 1.8 9.0
Polyunsaturated fatty acids 0.5 2.3
Energy from carbohydrate (%) 78.3 40.4
Energy from fat (%) 8.8 43.1
Metabolizable energy (MJ per meal) 2.31 2.17‡
2.25§
ND, not determined.
* Data refer to all food eaten. Any uneaten food was analysed and subtracted
from the total.
† Including 300 ml semi-skimmed milk and 250 ml orange juice.
‡ Days 2–28.
§ Test day 29.
and plasminogen-activator inhibitor-1 antigen (PAI-1) deter-
mination; K3 EDTA for ultracentrifugation, and lithium-
heparin for apolipoprotein B-48 (apoB-48) measurement.
The citrate tubes were then held at room temperature until
required for the analytical procedure. Other serum samples
were held at þ48 and determinants analysed on the day of
collection. Where this was not so, samples were held at þ48
and were analysed within 24 h of collection, except for insulin,
C-peptide, t-PA, PAI-1 and apoB-48 samples, which were
held at - 708 and analysed in a single run at the end of the
study. Serum glucose, insulin and C-peptide were determined
by the methods described in Frape et al. (1997b). Triacylgly-
cerols (TAG) were measured using a Hitachi 717 instrument
(Boehringer Mannheim UK Ltd., Lewes, East Sussex, UK) as
the difference between serum total and free glycerol concen-
trations, using a kit (Sigma Diagnostics, Poole, Dorset, UK),
employing a colorimetric reaction before and after enzymic
hydrolysis of the TAG. NEFA were measured by means of a
colorimetric reaction following the formation of acyl-CoA,
using a Hitachi 911 instrument, with a kit (Wako Chemicals
GmbH, Neuss, Germany).
Platelet aggregation was measured using ADP and col-
lagen as agonists, having final concentrations of 18.2 mmol/l
and 0.17 mg/ml respectively. Maximum aggregation and its
maximum rate were assessed within 5 min of the agonist
addition in a platelet aggregometer (Bio-Data PAP-4C;
Alpha Laboratories, Eastleigh, Hants., UK), using platelet-
rich plasma. t-PA activity, measured in the first six pairs of
subjects, and PAI-1 antigen were assessed using commer-
cial kits (Catalogue nos. 1103 and 210221; Biopool, Umea,
Sweden). ApoB-48 in plasma was determined using a
specific ELISA (Lovegrove et al. 1996) by Dr B. J.
Gould, School of Biological Sciences, University of
Surrey, Guildford, Surrey GU2 5XH, UK. VLDL-TAG
and remnant TAG were determined by analysis of the
glycerol content of the Svedberg flotation unit Sf, 20–400
lipid fraction after density-gradient ultracentrifugation
(Terpstra, 1985). Serum LDL-cholesterol was estimated
using the method of Friedewald et al. (1972). Urine samples
taken at 130 min following glucose consumption on days 1
and 29 were assessed ‘blind’ for glucose, using N-MultistixÒ
SG (Bayer Diagnostics plc, Evans House, Basingstoke,
Hants., UK). The intra-assay CV for the determinations
were respectively (%): glucose 1.3, total glycerol 0.9, free
glycerol 3.6, TAG 3.7, NEFA 2.2, Sf 20–400-TAG 11.4,
apoB-48 3.8, t-PA 7.9, PAI-1 4.9. The intra-assay CV for
platelet aggregation varied from 1.7 to 8.3 % for the various
measurements. For maximum aggregation with ADP and
collagen intra-assay CV were 3.4 and 2.1 % respectively
and for collagen lag time 8.3 %. The inter-assay CV for the
W : H measurement was 1.72 %. The tendency of platelets to
disaggregate once aggregated over a 5 min period under the
influence of ADP was scored ‘blind’. The range of scoring
was þ3 to - 5; platelets continuing to aggregate strongly were
scored þ3 and those disaggregating rapidly were scored - 5.
Statistical methods
Responses for all repeated measurement variables were
summarized at individual subject level by area under the
curve (AUC; Altman, 1991), calculated by applying the
trapezium rule for the OGTT response on days 1 and 29 and
for the period 09.00–13.20 hours on day 29. The baseline
for AUC was zero. Where the times of blood sampling
deviated by more than 0.5 min from the nominal time, the
actual time was used in the trapezium calculations. Treat-
ment comparisons were also made between zero-time and
60 min post glucose dose (peak serum glucose) and between
treatments at 12.00 hours, when the serum NEFA differ-
ences were expected, from evidence in previous studies
(Frape et al. 1997a), to be maximum. Variables not nor-
mally distributed were log-transformed towards normality.
The results were compared by t test, and SEM and CI
indicate the variation within treatment. The level of sig-
nificance selected for treatment differences between single
time-point mean values in Figs. 1–6 was P < 0.05.
The Pearson correlation coefficient was employed to
assess associations. All comparisons were carried out with
SPSS for Windows (Statistical Package for the Social
Science, 1993) and where appropriate by Microsoft Excel
version 5.0a for Windows software (Microsoft Corporation,
Seattle, WA, USA).
Ethical considerations
The protocol for the experiment was approved by the
Huntingdon Area Medical Ethics Committee and all sub-
jects gave informed written consent to participate.
Results
There was no significant difference between treatments for
fasting blood characteristics on either day 1 or day 29, or for
the AUC values of glucose, insulin, TAG or NEFA on day 1
(Table 2). The natural logarithm of fasting and OGTT
values for insulin, and OGTT values for C-peptide, were
used in the analysis.
Insulin
Treatment L led to a smaller OGTT insulin ln AUC
(P = 0.038) compared with treatment M on day 29 (Fig. 1),
and it caused a smaller increase within subject from day 1 to
day 29 in insulin ln AUC than the increase within subject
resulting from treatment M (P = 0.0036; Table 3).
Glucose
Three subjects in each treatment group demonstrated gly-
cosuria during the OGTT on day 1. On day 29, the same
three in treatment M continued to excrete glucose, but none
of those in treatment L did so. Treatment L led to a smaller
OGTT glucose AUC on day 29 compared with treatment M
(P = 0.0056; Fig. 2), and it caused a decrease within subject
from day 1 to day 29 in glucose AUC compared with an
increase for treatment M (P = 0.0057; Table 3). Day 1
OGTT glucose AUC was correlated with day 1 OGTT
NEFA AUC (r 0·52, P= 0.0098).
C-peptide
C-peptide was measured during the OGTT on day 29 only
and the results for eleven pairs of subjects are given, as one
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pair exhibited outlier responses. The treatment comparison
indicated that treatment L was associated with a smaller
mean increment in serum ln C-peptide concentration over
the 2 h of the OGTT than that in treatment M (L, 4.76 (SEM
0.02) v. M, 4.85 (SEM 0.02) mg/l, P = 0.026; Fig. 3).
Triacylglyerols, non-esterified fatty acids, free glycerol
and lipoproteins
On day 29 the OGTT TAG AUC was not significantly larger
for the L group than for the M group (P = 0.74; Table 4 and
Fig. 4). The origin of the TAG was apparently different
between treatments during the OGTT. At this time the
serum TAG for treatment L compared with M was derived
to a greater extent from the lipoprotein fraction Sf 20–400
(P = 0.016; Table 5) and TAG derived from the fraction Sf
> 400 was scant in both groups. The difference between
treatments in plasma apoB-48 concentration during the
period 13.20–15.00 hours was not significant (P = 0.086;
Table 5).
NEFA AUC during the OGTT was considerably lower for
the L group than for the M group (P = 0.0001). The NEFA
values were also lower at the start of the OGTT (13.30
hours) and at each collection time until 15.00 hours for
treatment L than those for treatment M (P = 0.0048). NEFA
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Table 2. Serum fasting values for insulin (mU/l), glucose, triacylglycerol (TAG), non-esterified fatty acids (NEFA), and total and LDL-cholesterol
(mmol/l) before (day 1) and after 28 d (day 29) of receiving a high-carbohydrate low-fat corn flakes breakfast (L) or a moderately-fatty pasty
breakfast (M) and areas under the curves (AUC) of serum values (mmol/l.min) on day 1 during a morning oral glucose tolerance test (OGTT)
before allocation to treatment of healthy middle-aged men*
(Values are means with their standard errors for twelve subjects, except for non-normally distributed fasting insulin where values are medians and
interquartile ranges (IQR))
Day 1 pretreatment Day 29
L M L M
Mean SE Mean SE Mean SE Mean SE
(Median) (IQR) (Median) (IQR) (Median) (IQR) (Median) (IQR)
Fasting values
Insulin (ln) 6.55 6.43 8.65 3.78 8.30 6.98 8.65 3.98
Glucose 5.10 0.17 4.98 0.12 5.19 0.17 5.10 0.11
TAG 1.30 0.34 1.32 0.21 1.48 0.40 1.27 0.20
NEFA 0.47 0.09 0.41 0.03 0.46 0.05 0.45 0.04
Total cholesterol 5.69 0.41 5.85 0.31 5.43 0.38 5.90 0.32
LDL-cholesterol 3.83 0.34 3.97 0.23 3.64 0.31 4.03 0.25
OGTT AUC
Insulin (ln; mU/l.min) 390.2 20.5 390.1 16.5
Glucose 824.8 56.5 739.3 28.6
TAG 158.2 38.2 160.1 24.9
NEFA 24.6 4.9 23.0 3.7
* For details of subjects and procedures, see pp. 324–325 and for details of composition of breakfast meals, see Table 1.
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Fig. 1. Serum ln insulin concentrations (mU/l) for twelve healthy middle-
aged men after 28 d of receiving a high-carbohydrate low-fat corn flakes
breakfast (W) or a moderately-fatty pasty breakfast (X), during an oral
glucose tolerance test (OGTT) in the afternoon after a breakfast meal at
09.00 hours. Points are arithmetic means with CI represented by
vertical bars. Mean value was significantly different from that for low-
fat breakfast: *P < 0:05. For details of subjects and procedures, see
pp. 324–325 and for details of breakfast meals, see Table 1.
Table 3. Areas under the curves (AUC) of serum glucose and insulin
responses to treatment during the oral glucose tolerance test (OGTT)
between 13.30 and 15.30 hours on day 29, and the mean within
subject change in AUC response from day 1 to day 29 during the
OGTT for healthy middle-aged men receiving a high-carbohydrate
low-fat corn flakes breakfast (L) or a moderately-fatty pasty breakfast
(M) for 28 d*
(Values are means with their standard errors for twelve subjects)
Glucose Insulin
(mmol/l.min) ln(mU/l.min)
Day 29
Treatment L Mean 797.2 402.0
SEM 34.6 20.8
Treatment M Mean 970.0 449.3
SEM 56.4 13.4
Statistical significance of difference: P 0.0056 0.038
Days (1–29)
Treatment L Mean ¹27.6 11.8
SEM 52.7 11.0
Treatment M Mean 230.6 59.2
SEM 57.6 12.4
Statistical significance of difference: P 0.0057 0.0036
* For details of subjects and procedures, see pp. 324–325 and for details of
composition of breakfast meals, see Table 1.
values at 60 min post-OGTT were lower than those pre-OGTT
in both groups (P = 0.0001); the decline in NEFA concentra-
tion did not commence until 30 min post-OGTT (Fig. 5). The
OGTT free glycerol AUC values for the two treatments were
not significantly different (P = 0.39; Fig. 6).
The difference between treatments for serum NEFA
reached a maximum at 12.00 hours on day 29, before the
OGTT, when serum free glycerol and NEFA were greater
for the M group than for the L group (P = 0.0008 and
P < 0.0001 respectively; Figs. 5 and 6).
After breakfast in the morning on day 29 (09.00–13.20
hours) NEFA AUC for treatment L was only 59 % of that for
treatment M (Fig. 5; P < 0.0001). The free glycerol AUC
responses were also different (P = 0.049; Fig. 6). On the other
hand, serum TAG AUC values during this interval were very
similar for the two treatments (P = 1.00; Table 4 and Fig. 4).
Physical characteristics
There was no significant difference between treatments in
physical characteristics on day 1, or in body weight and
BMI changes during the experiment. However, treatment M
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Fig. 2. Serum glucose concentrations (mmol/l) for twelve healthy
middle-aged men after 28 d of receiving a high-carbohydrate low-fat
corn flakes breakfast (W) or a moderately-fatty pasty breakfast (X),
during an oral glucose tolerance test (OGTT) in the afternoon after a
breakfast meal at 09.00 hours. Points are means with their standard
errors represented by vertical bars. Mean values were significantly
different from those for the low-fat breakfast; *P < 0:05. For details of
subjects and procedures, see pp. 324–325 and for details of break-
fast meals, see Table 1.
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Fig. 3. Serum ln C-peptide concentrations (mg/l) for eleven healthy
middle-aged men after 28 d of receiving a high-carbohydrate low-fat
corn flakes breakfast (W) or a moderately-fatty pasty breakfast (X),
during an afternoon oral glucose tolerance test (OGTT). A breakfast
was given at 09.00 hours. One pair of subjects of the twelve pairs was
excluded on the grounds of extended responses following breakfast
meal on day 29. Points are arithmetic means with CI represented by
vertical bars. For details of subjects and procedures, see pp. 324–
325 and for details of breakfast meals, see Table 1.
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Fig. 4. Serum triacylglycerol (TAG) concentrations (mmol/l) for twelve
healthy middle-aged men after 28 d of receiving a high-carbohydrate
low-fat corn flakes breakfast (W) or a moderately-fatty pasty breakfast
(X). After a breakfast meal at 09.00 hours serum TAG were measured
during the morning and again over 120 min of an oral glucose
tolerance test (OGTT) in the afternoon. Points are means with their
standard errors represented by vertical bars. For details of subjects
and procedures, see pp. 324–325 and for details of breakfast meals,
see Table 1.
Table 4. Areas under the curves (AUC) of serum triacylglycerol (TAG)
and non-esterified fatty acid (NEFA) responses to treatment after
breakfast on day 29 (09.00–13.20 hours) and during the oral glucose
tolerance test (OGTT; 13.30–15.30 hours) on day 29 for healthy
middle-aged men receiving a high-carbohydrate low-fat corn flakes
breakfast (L) or a moderately-fatty pasty breakfast (M) for 28 d*
(Values are means with their standard errors for twelve subjects)
TAG NEFA
(mmol/l.min) (mmol/l.min)
09.00–13.20 hours
Treatment L Mean 440 60.9
SEM 101 4.2
Treatment M Mean 435 103.5
SEM 66 5.8
Statistical significance of difference: P 1.0 < 0.0001
13.30–15.30 hours
Treatment L Mean 215 24.6
SEM 48 1.97
Treatment M Mean 199 43.0
SEM 38 2.64
Statistical significance of difference: P 0.74 < 0.0001
* For details of subjects and procedures, see pp. 324–325 and for details of
composition of breakfast meals, see Table 1.
increased the W : H measurement (0.016 (SD 0.028)); com-
pared with a loss amongst the treatment L group ( - 0.015 (SD
0.038); treatment difference, P = 0.035). This was
accounted for mainly by a change in waist measurement
(P = 0.063). However, there was an opposing change in hip
measurement (P = 0.37), and so the apparent treatment
difference in W : H may have been chance. In order to
exclude any spurious influences or treatment effects, the
correlations of metabolic variables with the W : H are based
on the W : H values for day 1 only.
Metabolic factors of thrombus formation and
atherosclerosis
There was no significant treatment difference for platelet
aggregation, or for PAI-1 antigen, on day 29. On day 29
plasma t-PA showed a linear diurnal increase during the
period 09.00–13.20 hours with treatment L (P = 0.0008),
whereas no significant increase occurred with treatment M
(P = 0.8). The fatty meal was associated with a decrease in
plasma t-PA activity during the first postprandial hour.
Correlations were detected in the measurements on day 1
for several risk factors. The values indicate an association
between W : H and serum glucose AUC (r 0.49, P = 0.016),
insulin AUC (r 0.42, P = 0.042), fasting t-PA activity
(r ¹0.63, P = 0.028) and fasting LDL-cholesterol (r 0.49,
P = 0.015). Serum insulin AUC was correlated with plasma
PAI-1 antigen (r 0.74, P < 0.0001). For the values on days 1
and 29 combined within subject, where there was no
significant treatment effect, serum TAG AUC was corre-
lated with fasting platelet aggregation lag time (agonist
collagen; r - 0.42, P = 0.043) and with fasting platelet
maximum aggregation (agonist collagen; r 0.62, P =
0.0013). Fasting LDL-cholesterol was also correlated with
fasting platelet aggregation lag time (agonist collagen;
r ¹0.52, P = 0.0089). The tendency of platelets to disag-
gregate under the influence of ADP, an effect previously
found to be correlated with risk of heart disease (Elwood
et al. 1991), was not significantly correlated with W : H
(r ¹0.35, P = 0.06).
Discussion
Glucose tolerance
Decreased insulin sensitivity and elevated fasting serum
insulin and glucose concentrations are related to risk factors
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Table 5. Mean plasma Svedberg flotation unit (Sf ) 20–400 triacylgly-
cerol (TAG; mmol/l) and apolipoprotein B-48 (apoB-48; mg/l) pre-
glucose dose (13.20 hours) and during the glucose tolerance test on
day 29 for healthy middle-aged men receiving a high-carbohydrate
low-fat corn flakes breakfast (L) or a moderately-fatty pasty breakfast
(M) for 28 d*
(Mean values with their standard errors for twelve subjects)
Sf 20–400
Time of day
TAG ApoB-48†
(hours) Treatment Mean SEM Mean SEM
13.20 L 0.99 0.19 2.04 0.10
M 0.57 0.23 2.52 0.29
14.30 L 1.02 0.22 1.88 0.08
M 0.60 0.25 2.45 0.26
15.00 L 0.95 0.20
M 0.63 0.31
15.30 L 0.95 0.21
M 0.54 0.26
* For details of subjects and procedures, see pp. 324–325 and for details of
breakfast meals, see Table 1.
† ApoB-48 sample at 14.30 hours pooled with the sample at 15.00 hours.
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Fig. 5. Serum non-esterified fatty acid (NEFA) concentrations (mmol/l)
for twelve healthy middle-aged men after 28 d of receiving a high-
carbohydrate low-fat corn flakes breakfast (W) or a moderately-fatty
pasty breakfast (X). After a breakfast meal at 09.00 hours serum NEFA
were measured during the morning and again over 120 min of an oral
glucose tolerance test (OGTT) in the afternoon. Points are means with
their standard errors represented by vertical bars. Mean values are
significantly different from those for the low-fat breakfast: P < 0:05. For
details of subjects and procedures, see pp. 324–325 and for details of
breakfast meal, see Table 1.
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Fig. 6. Serum free glycerol concentrations (mmol/l) for twelve healthy
middle-aged men after 28 d of receiving a high-carbohydrate low-fat
corn flakes breakfast (W) or a moderately-fatty pasty breakfast (X).
After a breakfast meal at 09.00 hours serum glycerol was measured
during the morning and again over 120 min of an oral glucose
tolerance test (OGTT) in the afternoon. Points are means with their
standard errors represented by vertical bars. Mean value was sig-
nificantly different from that for low-fat breakfast: *P < 0:05. For
details of subjects and procedures, see pp. 324–325 and for details
of breakfast meal, see Table 1.
of heart disease (Ohlson et al. 1989). In the present study
treatment M led to higher glucose, insulin and C-peptide
responses (P < 0.05) during the OGTT on day 29. The
changes in glucose tolerance and insulin response from
day 1 to day 29 were also significantly different between
treatments. Such differences over time could have resulted
from conducting the measurements in the morning of day 1
and the afternoon of day 29. However, the differences were
in full accord with our previous observations that whereas
carbohydrate meals given in the morning and afternoon
yielded similar glucose AUC responses (morning 26.3
(SE 1.3) v. afternoon 26.6 (SE 0.82) mmol/l.h; P = 0.8),
fatty meals of similar energy content yielded different
glucose AUC responses (morning 22.2 (SE 0.6) v. afternoon
23.9 (SE 0.5) mmol/l.h; P = 0.004) and subjects given the
fatty lunch following the fatty breakfast yielded larger
glucose AUC reponses than did those given the fatty
lunch following the carbohydrate breakfast (respectively
morning 23.9 (SE 0.5) v. afternoon 22.4 (SE 0.4), mmol/
litre.h; P = 0.03; Frape et al. 1997b). Thus, small differences
in fat intake at breakfast can influence glucose tolerance
several hours later. In the present study, serum insulin AUC
was also highly correlated with plasma PAI-1 antigen
levels, consistent with observations by Lopez-Segura et al.
(1996) and Toft et al. (1997) in men, and reinforcing a
possible link of insulin function with risk factors of
thromboembolic disease.
Origin of postprandial triacylglycerol
Lui et al. (1983) reported that the daily intake by healthy
subjects of large amounts of carbohydrate containing 220–
250 g sucrose/kg, stimulated TAG synthesis and release as
endogenous apoB-100 VLDL-TAG in the fasting state. In
our study, treatment M provided 20 g more fat and 57 g less
carbohydrate than treatment L at breakfast, yet the post-
prandial serum TAG concentration was similar for the two
treatments. The provision of natural sucrose (12 g fructose
residue; in orange juice with the carbohydrate meal) may
have contributed to this similarity. The higher afternoon
OGTT plasma Sf 20–400-TAG concentration with treat-
ment L (P = 0.016) probably reflected the effect of dietary
carbohydrate on the plasma VLDL response (Jeppesen et al.
1995).
Waist:hip circumference and its relation to other risk
factors
Zamboni et al. (1997) found that although both visceral
adipose tissue and glucose intolerance increased with age,
differences in glucose tolerance disappeared after adjust-
ment for visceral adipose tissue differences. Increased
W : H, an anthropometric measure of abdominal fat deposi-
tion, is correlated with risk of atherosclerosis, thrombosis,
and stroke (Walker et al. 1996). In the present study, on day 1
W : H was positively correlated with fasting serum LDL-
cholesterol, serum insulin AUC and glucose AUC and
negatively with plasma t-PA activity. Serum insulin AUC
was correlated with plasma PAI-1 antigen level. Abdominal
obesity is correlated negatively with t-PA antigen and
positively with PAI-1 activity (Landin et al. 1990). The
relationship of W : H with the metabolic characteristics
measured may be a consequence of the greater lipolytic
activity of abdominal fat compared with gluteofemoral fat
(Landin et al. 1990), which may, therefore, differentially
influence postprandial serum NEFA concentration. Coon
et al. (1992) found a correlation in healthy men between
W : H and the exponential rate of decline of plasma NEFA
concentration during euglycaemic hyperinsulinaemic
clamping; although no significant correlation (P < 0.05) of
AUC NEFA with the smaller range in W : H was found in our
data on day 1.
Dietary fat content and serum non-esterified
fatty acid concentration
The morning serum TAG concentrations were similar for
the isoenergetic L and M treatments, in agreement with the
evidence (Whitley et al. 1997) that different inverse propor-
tions of carbohydrate relative to fat in an isoenergetic meal
lead to similar postprandial plasma TAG concentrations.
Despite this similarity we found greater circulating serum
levels of NEFA and glycerol throughout the day until 15.30
hours with treatment M than with treatment L. These
differences may have stemmed from differences in leak-
back (Frayn, 1993). Circulating TAG in treatment L is likely
to have been predominately that of VLDL, and VLDL-TAG
is known to be cleared more slowly than chylomicron TAG
(Havel, 1994), which could have led to a slower NEFA
release in treatment L.
During starvation the NEFA : glycerol ratio of release
from subcutaneous adipose tissue is close to 3:1 (Samra et al.
1996). At 13.30 hours with treatment M the value was 6:1
and serum NEFA was elevated. This may indicate the
combined influence, principally of HSL activity, but also
a resistance to NEFA clearance, as the subsequent increase
in serum insulin rapidly decreased serum levels of both
NEFA and glycerol (Figs. 5 and 6). However, Frayn et al.
(1997) reported that 80 % of circulating NEFA 180–
300 min postprandially arose from the action of LPL in
healthy subjects. On the other hand, their diets contained
considerably more carbohydrate than did diet M, and the
inhibition of lipolysis by HSL can be blunted in insulin-
resistant states (Havel, 1972). In healthy subjects, plasma
insulin concentrations exceeding 14–17 mU/l suppress HSL
(Frayn et al. 1995). Serum insulin greatly exceeded this
limit 1 h after breakfast with both treatments L and M (Frape
et al. 1997b), when the treatment difference in serum NEFA
was not significant, but by 3–4 h after breakfast the serum
insulin level was below the limit with treatment M when the
treatment difference in NEFA (Fig. 5) was greatest. It is
possible, therefore, that treatment difference in serum
NEFA concentration at 12.00 hours resulted to a consider-
able extent from treatment differences in HSL activity.
The fat source in both treatments was principally dairy,
that has been shown to cause a larger NEFA response than
that observed with olive oil when both were added to potato
(Rasmussen et al. 1996), and the use by us of a dairy-fat
source may have contributed to the large treatment differ-
ence. Moreover, Kiens & Richter (1996) asserted that high-
glycaemic-index carbohydrates cause less insulin resistance
than low-glycaemic-index carbohydrates, through lower
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serum NEFA levels. An increased circulating concentration
of NEFA is known to suppress glucose oxidation (Ferran-
nini et al. 1983), and Pei et al. (1995) reported that plasma
concentrations of both NEFA and glycerol were commen-
surate with the degree of resistance to insulin-mediated
glucose disposal. Elevated circulating NEFA concentrations
impair the action of key proteins in insulin binding and
signal propagation in isolated hepatocytes by mechanisms
related to their oxidation, and they reduce the number of
hepatic binding sites for insulin (Svedberg et al. 1990,
1991). Moreover, an inability to adequately suppress post-
prandial plasma NEFA concentration is positively asso-
ciated with elevated plasma PAI-1 activity in men (Toft
et al. 1997). The results of the present experiment indicate
that with fat of the composition employed, a relatively small
amount at breakfast can lead to high circulating concentra-
tions of NEFA that persists for 6 h. These concentrations
can then bring about a depression in glucose tolerance and
an elevated insulin response, compared with the response to
a carbohydrate breakfast.
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